Jackson Peter
Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK.
Br J Clin Pharmacol. 2012 Jun;73(6):888-92. doi: 10.1111/j.1365-2125.2012.04231.x.
The UK postgraduate curriculum in clinical pharmacology and therapeutics (CPT) incorporates the common competencies required of all physicians and shows how trainees from other specialties, including primary care, can train in CPT. Various models of training and assessment are possible. Evolution of the current system to meet new challenges would maintain an established tradition, with a ready source of training funds. However, this would require greater input from all consultants in CPT, including the training and assessment of trainees. A joint venture with the Faculty of Pharmaceutical Medicine would have the advantage, if the Faculty agreed, of introducing ready-made curriculum modules and assessment tools that have been accepted by the General Medical Council. However, extra modules relevant to CPT would have to be constructed to complement the common areas already in the pharmaceutical medicine curriculum, and there would be a perceived loss of the independence that clinical pharmacologists currently enjoy when making decisions about manufacturers' products. Abandoning externally approved training in CPT would allow the specialty to devise its own training and assessment in the necessary skills. Critically, however, this would impair the status of the specialty and would incur loss of financial support from postgraduate Deaneries. To attract high-calibre trainees, we must completely define CPT training and assessment structures. Most clinical pharmacologists seem to prefer to allow the current structures to evolve under external guidance. However, this will not succeed unless all trained clinical pharmacologists contribute to development of both the curriculum and specific assessment tools, and open their teaching and assessment skills to scrutiny.
英国临床药理学与治疗学(CPT)研究生课程纳入了所有医生所需的共同能力,并展示了包括初级保健在内的其他专业的受训人员如何接受CPT培训。培训和评估有多种模式。对现行系统进行改进以应对新挑战将延续既定传统,并拥有现成的培训资金来源。然而,这需要CPT领域的所有顾问加大投入,包括对受训人员的培训和评估。如果制药医学系同意,与其合资将具有优势,即引入已获英国医学总会认可的现成课程模块和评估工具。然而,必须构建与CPT相关的额外模块,以补充制药医学课程中已有的共同领域,而且在对制造商产品做出决策时,临床药理学家目前所享有的独立性会被认为有所丧失。放弃CPT领域外部批准的培训将使该专业能够自行设计必要技能的培训和评估。然而,至关重要的是,这将损害该专业的地位,并导致失去研究生医学教育中心的财政支持。为吸引高素质的受训人员,我们必须全面界定CPT培训和评估结构。大多数临床药理学家似乎更倾向于让现行结构在外部指导下发展。然而,除非所有受过培训的临床药理学家都为课程和具体评估工具的开发做出贡献,并使其教学和评估技能接受审查,否则这不会成功。